0001225208-21-003518.txt : 20210223 0001225208-21-003518.hdr.sgml : 20210223 20210223171227 ACCESSION NUMBER: 0001225208-21-003518 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210221 FILED AS OF DATE: 20210223 DATE AS OF CHANGE: 20210223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fitzgerald Joseph Michael CENTRAL INDEX KEY: 0001484186 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 21666735 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2021-02-21 0000885725 BOSTON SCIENTIFIC CORP BSX 0001484186 Fitzgerald Joseph Michael 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP & Pres, Interven Cardio Common Stock 2021-02-21 4 M 0 3894.0000 0.0000 A 248824.0000 D Common Stock 2021-02-21 4 F 0 1922.0000 38.0300 D 246902.0000 D Common Stock 2021-02-22 4 M 0 4056.0000 0.0000 A 250958.0000 D Common Stock 2021-02-22 4 F 0 2002.0000 39.2000 D 248956.0000 D Common Stock 68312.0000 I By 401(k) Common Stock 6038.0000 I By Children Deferred Stock Units 2021-02-21 4 M 0 3894.0000 0.0000 D 2023-02-21 Common Stock 3894.0000 7790.0000 D Deferred Stock Units 2021-02-22 4 M 0 4056.0000 0.0000 D 2021-02-22 Common Stock 4056.0000 0.0000 D Performance Share Units 2021-02-22 4 A 0 13134.0000 0.0000 A 2022-12-31 2022-12-31 Common Stock 13134.0000 13134.0000 D Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. /s/ Scott G. Hodgdon, Attorney-in-Fact 2021-02-23